2023 World Conference on Lung Cancer (Posters)-EP13.03. A Single Arm Phase II Study of Tislelizumab Plus Anlotinib as Maintenance Therapy in Patients with Extensive-stage Small Cell Lung Cancer

EP13.03. A Single Arm Phase II Study of Tislelizumab Plus Anlotinib as Maintenance Therapy in Patients with Extensive-stage Small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

This study evaluated the efficacy and safety of the combination of tislelizumab and anlotinib as maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC) after platinum-based chemotherapy. Tislelizumab is an anti-programmed cell death protein 1 monoclonal antibody that has been approved for the treatment of advanced non-small cell lung cancer in China. The study included 8 patients who had received first-line platinum-based chemotherapy. The median follow-up was 9.5 months. <br /><br />The combination therapy showed promising efficacy and manageable safety. One patient achieved a partial response, and four patients had stable disease. The six-month progression-free survival rate was 25%, and the median progression-free survival was 2.8 months. The median overall survival was 16.9 months. <br /><br />The safety profiles of tislelizumab and anlotinib were assessed and reported. Adverse events included cough, hoarse voice, musculoskeletal pain, diarrhea, hypertension, hyperglycemia, hyponatremia, superior vena cava embolus, hyperbilirubinemia, and hypercreatinemia.<br /><br />The baseline characteristics of the patients were also summarized, including age, gender, performance status, smoking status, and sites of metastases. The prior treatment of the patients, including types of chemotherapy and best response, was also described.<br /><br />In conclusion, the combination of tislelizumab and anlotinib as maintenance therapy in ES-SCLC showed promising efficacy and manageable safety. The study provides initial outcomes and data on the use of this combination therapy in this patient population. Further studies with larger sample sizes are warranted to confirm these findings.

Asset Subtitle

YK Shi

Meta Tag

Speaker YK Shi

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

tislelizumab

anlotinib

maintenance therapy

extensive-stage small cell lung cancer

platinum-based chemotherapy

efficacy

safety

partial response

progression-free survival

overall survival